Pre-treatment serum testosterone level can be a useful factor to predict the improvement in bladder outlet obstruction by tadalafil for male patients with lower urinary tract symptoms induced by benign prostatic obstruction.


Journal

The aging male : the official journal of the International Society for the Study of the Aging Male
ISSN: 1473-0790
Titre abrégé: Aging Male
Pays: England
ID NLM: 9808210

Informations de publication

Date de publication:
Dec 2020
Historique:
pubmed: 18 1 2019
medline: 26 10 2021
entrez: 18 1 2019
Statut: ppublish

Résumé

To investigate possible pre-treatment factors related to the therapeutic effect of tadalafil on bladder outlet obstruction (BOO). Eighty untreated outpatients with lower urinary tract symptoms (LUTS) due to BOO received 5 mg tadalafil daily for 12 months. Subjective symptoms and objective findings were evaluated before and 12 months after treatment. At 12 months, the patients were divided into two groups according to an improvement grade in BOO index (BOOI). Patient characteristics including age, serum total testosterone level (TT), PSA, and prostate volume, and subjective and objective parameters on LUTS were set as candidates of pre-treatment factors, and the parameters that influenced the improvement of BOO were statistically analysed. A total of 69 patients with mean age of 69.8 years and mean prostate volume of 48.8 mL were included. Subjective symptoms and BOOI were significantly ameliorated after 12 months. In terms of an improvement of BOOI, 30 patients (43.5%) showed insignificant improvement in BOO, whereas 39 patients (56.5%) exhibited excellent improvement. Comparison of pre-treatment factors between the groups showed that TT was the only independent predictor related to the improvement in BOO. The improvement of BOO was significantly better in patients with higher TT. Pre-treatment TT was considered to be a useful predictor of therapeutic effects of tadalafil for BOO.

Identifiants

pubmed: 30651033
doi: 10.1080/13685538.2018.1563777
doi:

Substances chimiques

Testosterone 3XMK78S47O
Tadalafil 742SXX0ICT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

641-647

Auteurs

Yoshihisa Matsukawa (Y)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yoshie Kanada (Y)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Shun Takai (S)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Satoshi Inoue (S)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Tsuyoshi Majima (T)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yasuhito Funahashi (Y)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Masashi Kato (M)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Tokunori Yamamoto (T)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Momokazu Gotoh (M)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH